<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28777203</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>04</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>04</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1935-3227</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2018</Year>
              <Season>Jan/Feb</Season>
            </PubDate>
          </JournalIssue>
          <Title>Journal of addiction medicine</Title>
          <ISOAbbreviation>J Addict Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Review of Alprazolam Use, Misuse, and Withdrawal.</ArticleTitle>
        <Pagination>
          <StartPage>4</StartPage>
          <EndPage>10</EndPage>
          <MedlinePgn>4-10</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/ADM.0000000000000350</ELocationID>
        <Abstract>
          <AbstractText>: Alprazolam is one of the most widely prescribed benzodiazepines for the treatment of generalized anxiety disorder and panic disorder. Its clinical use has been a point of contention as most addiction specialists consider it to be highly addictive, given its unique psychodynamic properties which limit its clinical usefulness, whereas many primary care physicians continue to prescribe it for longer periods than recommended. Clinical research data has not fully shed light on its "abuse liability," yet it is one of the most frequently prescribed benzodiazepines. "Abuse liability" is the degree to which a psychoactive drug has properties that facilitate people misusing it, or becoming addicted to it, and is commonly used in the literature. We have replaced it in our manuscript with "misuse liability" as it reflects a more updated terminology consistent with the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). In this paper, we have reviewed alprazolam's indications for use, its effect on pregnant women, misuse liability, withdrawal syndrome, pharmacodynamic properties, and suggest better clinical prescription practice of alprazolam by presenting an indepth theory of its clinical effects with use and withdrawal.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ait-Daoud</LastName>
            <ForeName>Nassima</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>University of Virginia, Department of Psychiatry and Neurobehavioral Sciences. Charlottesville, VA (NA-D, SS, DB); Sentara RMH Medical Center: 2010 Health Campus Drive, Harrisonburg, VA (ASH).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamby</LastName>
            <ForeName>Allan Scott</ForeName>
            <Initials>AS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharma</LastName>
            <ForeName>Sana</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blevins</LastName>
            <ForeName>Derek</ForeName>
            <Initials>D</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>T32 DA007294</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Addict Med</MedlineTA>
        <NlmUniqueID>101306759</NlmUniqueID>
        <ISSNLinking>1932-0620</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>12794-10-4</RegistryNumber>
          <NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YU55MQ3IZY</RegistryNumber>
          <NameOfSubstance UI="D000525">Alprazolam</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000525" MajorTopicYN="N">Alprazolam</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016584" MajorTopicYN="N">Panic Disorder</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063487" MajorTopicYN="Y">Prescription Drug Misuse</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors report no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>8</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>8</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28777203</ArticleId>
        <ArticleId IdType="mid">NIHMS947341</ArticleId>
        <ArticleId IdType="pmc">PMC5846112</ArticleId>
        <ArticleId IdType="doi">10.1097/ADM.0000000000000350</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>ACOG. American College of Obstetricians and Gynecologists Practice Bulletin No. 87 November 2007: Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2007;110:1179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17978143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adler LE, Bell J, Kirch D, et al.  Psychosis associated with clonidine withdrawal. Am J Psychiatry. 1982;139:110–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6119907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albeck JH. Withdrawal and detoxification from benzodiazepine dependence: a potential role for clonazepam. J Clin Psychiatry. 1987;48(Suppl):43–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2889723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altshuler L, Cohen L. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Year Book Psychiatry Appl Mental Health. 1997;1997:491.</Citation>
        </Reference>
        <Reference>
          <Citation>Apelt S, Schmauss C, Emrich H. Preference for alprazolam as opposed to diazepam in benzodiazepine-dependent psychiatric inpatients. Pharmacopsychiatry. 1990;23:70–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1971118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol. 2005;8:293–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15576000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ballenger JC, Burrows GD, DuPont RL, et al.  Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial: I. Efficacy in short-term treatment Arch Gen Psychiatry. 1988;45:413–422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3282478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandelow B, Zohar J, Hollander E, et al.  WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders. World J Biol Psychiatry. 2008;9:248–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18949648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barker MJ, Greenwood KM, Jackson M, et al.  Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol. 2004;19:437–454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15033227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bentue-Ferrer D, Reymann J, Tribut O, et al.  Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam. Eur Neuropsychopharmacol. 2001;11:41–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11226811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Björkqvist SE, Isohanni M, Mäkelä R, et al.  Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo. Acta Psychiatr Scand. 1976;53:333–342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">785949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Browne J, Hauge K. A review of alprazolam withdrawal. Drug Intelligence Clin Pharm. 1986;20:837–841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3536383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention. Drug overdose deaths: Florida, 2003–2009. MMWR. 2011;60:869–872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21734633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciraulo DA, Barnhill JG, Ciraulo AM, et al.  Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. J Clin Pharmacol. 1997;37:64–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9048275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curran HV, Bond A, O’Sullivan G, et al.  Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. Psychol Med. 1994;24:969–976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7892364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA. 1988;85:5274–5278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC281732</ArticleId>
            <ArticleId IdType="pubmed">2899326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dilsaver SC, Peck JA, Traumata D, et al.  Treatment with carbamazepine may enhance ( 2-noradrenergic autoreceptor sensitivity. Biol Psychiatry. 1993;34:551–557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8274582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolovich LR, Addis A, Vaillancourt JR, et al.  Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ. 1998;317:839–843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC31092</ArticleId>
            <ArticleId IdType="pubmed">9748174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eriksson E, Carlsson M, Nilsson C, et al.  Does alprazolam, in contrast to diazepam, activate alpha2-adrenoceptors involved in the regulation of rat growth hormone secretion? Life Sci. 1986;38:1491–1498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2871466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freiberger JJ, Marsicano TH. Alprazolam withdrawal presenting as delirium after cardiac surgery. J Cardiothorac Vasc Anesth. 1991;5:150–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1863727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fyer AJ, Liebowitz MR, Gorman JM, et al.  Discontinuation of alprazolam treatment in panic patients. Am J Psychiatry. 1987;144:303–308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3826428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fyer AJ, Liebowitz MR, Gorman JM, et al.  Effects of clonidine on alprazolam discontinuation in panic patients: a pilot study. J Clin Psychopharmacol. 1988;8:270–274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3209718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galpern WR, Miller LG, Szabo GK, et al.  Chronic benzodiazepine administration: IX. Attenuation of alprazolam discontinuation effects by carbamazepine. Biochem Pharmacol. 1991;42:99–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1662953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam. Clin Pharmacokinet. 1993;24:453–471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8513649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffiths RR, Wolf B. Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol. 1990;10:237–243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1981067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grohol J. Top 25 Psychiatric Medication Prescriptions for 2013. 2016 Available at:  https://psychcentral.com/lib/top-25-psychiatric-medication-prescriptions-for-2013/</Citation>
        </Reference>
        <Reference>
          <Citation>Heh CW, Sramek J, Herrera J, et al.  Exacerbation of psychosis after discontinuation of carbamazepine treatment. Am J Psychiatry. 1988;145:878–879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2898213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henderson A, Wright M, Pond S. Experience with 732 acute overdose patients admitted to an intensive care unit over six years. Med J Australia. 1993;158:28–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8417286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iguchi MY, Griffiths RR, Bickel WK, et al.  Relative abuse liability of benzodiazepines in methadone maintained populations in three cities. NIDA Res Monograph. 1989;95:364–365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2577040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002;53:39–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11773648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isbister GK, O’regan L, Sibbritt D, et al.  Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol. 2004;58:88–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1884537</ArticleId>
            <ArticleId IdType="pubmed">15206998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jonas JM, Cohon MS. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. J Clin Psychiatry. 1993;54(Suppl 25–45):46–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8262888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juergens S. Alprazolam and diazepam: addiction potential. J Subst Abuse Treatment. 1991;8:43–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2051498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kales A, Soldatos CR, Bixler EO, et al.  Diazepam: effects on sleep and withdrawal phenomena. J Clin Psychopharmacol. 1988;8:340–346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3183072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kantor SJ. A difficult alprazolam withdrawal. J Clin Psychopharmacol. 1986;6:124–125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3700701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein E, Uhde TW, Post RM. Preliminary evidence for the utility of carbamazepine in alprazolam withdrawal. Am J Psychiatry. 1986;143:235–236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2868666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klerman GL. Overview of the cross-national collaborative panic study: I. efficacy in short-term treatment. Arch Gen Psychiatry. 1988;45:407–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3282477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroll DS, Nieva HR, Barsky AJ, et al.  Benzodiazepines are prescribed more frequently to patients already at risk for benzodiazepine-related adverse events in primary care. J Gen Intern Med. 2016;31(9):1027–1034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4978684</ArticleId>
            <ArticleId IdType="pubmed">27177914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laegreid L, Olegrd R, Walström J, et al.  Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr. 1989;114:126–131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2562851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levenson JL.  The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill. 2. Arlington, Virginia: American Psychiatric Pub; 2011. </Citation>
        </Reference>
        <Reference>
          <Citation>Lucki I, Rickels K. The behavioral effects of benzodiazepines following long-term use. Psychopharmacol Bull. 1986;22:424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2877474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucki I, Rickels K, Geller AM. Chronic use of benzodiazepines and psycho-motor and cognitive test performance. Psychopharmacology. 1986;88:426–433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2871579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKenzie RR, Jr, Madadi P, Sharma TR. Alprazolam withdrawal delirium and brief reversible psychosis: a case report. Prim Care Companion CNS Disord. 2014:16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4321011</ArticleId>
            <ArticleId IdType="pubmed">25667806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moylan S, Staples J, Ward SA, et al.  The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol. 2011;31:647–652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21869686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mumford G, Evans S, Fleishaker J, et al.  Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Therapeut. 1995;57:356–365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7697954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Collaborating Centre for Mental Health. NICE guideline (CG192) London, UK: British Psychological Society and The Royal College of Psychiatrists; 2014. Antenatal and postnatal mental health: clinical management and service guidance—updated edition.</Citation>
        </Reference>
        <Reference>
          <Citation>Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectrums. 2005;10:49–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15618947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orzack MH, Friedman L, Dessain E, et al.  Comparative study of the abuse liability of alprazolam, lorazepam, diazepam, methaqualone, and placebo. Int J Addict. 1988;23:449–467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3061941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Páll A, Becs G, Erdei A, et al.  Pseudopheochromocytoma induced by anxiolytic withdrawal. Eur J Med Res. 2014;19:53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4196012</ArticleId>
            <ArticleId IdType="pubmed">25288254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patterson JF. Withdrawal from alprazolam dependency using clonazepam: clinical observations. J Clin Psychiatry. 1990;51(5, Suppl):47–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2335501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pecknold JC, Swinson RP, Kuch K, et al.  Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial: III. Discontinuation effects. Arch Gen Psychiatry. 1988;45:429–436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3282479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Penders T. Gabapentin (Neurontin): an adjunct for benzodiazepine withdrawal. Ommega Internations. 2015;1:1–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Rickels K, Schweizer E, Garcia Espana F, et al.  Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology. 1999;141:1–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9952057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Risse SC, Whitters A, Burke J, et al.  Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. J Clin Psychiatry. 1990;51:206–209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2335496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sachdev G, Gesin G, Christmas AB, et al.  Failure of lorazepam to treat alprazolam withdrawal in a critically ill patient. World J Crit Care Med. 2014;3:42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4021153</ArticleId>
            <ArticleId IdType="pubmed">24834401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SAMHSA. Drug Abuse Warning Network, 2011: national estimates of drug-related emergency department visits. Subst Abuse Mental Health Serv Administr. 2013;13:4760.</Citation>
        </Reference>
        <Reference>
          <Citation>Schmauss C, Apelt S, Emrich H. The seeking and liking potentials of alprazolam. Am J Psychiatry. 1988;145:128a–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3337279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmauss C, Apelt S, Emrich H. Preference for alprazolam over diazepam. Am J Psychiatry. 1989;146:408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2919707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schweizer E, Rickels K, Weiss S, et al.  Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry. 1993;50:51–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8422222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tollefson GD. Hyperadrenergic hypomania consequent to the abrupt cessation of clonidine. J Clin Psychopharmacol. 1981;1:93–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7298887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Marwijk H, Allick G, Wegman F, et al.  Alprazolam for depression. Cochrane Database Syst Rev. 2012:CD007139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6769182</ArticleId>
            <ArticleId IdType="pubmed">22786504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vander Weele CM, Porter-Stransky KA, Mabrouk OS, et al.  Rapid dopamine transmission within the nucleus accumbens: dramatic difference between morphine and oxycodone delivery. Eur J Neurosci. 2014;40:3041–3054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4358739</ArticleId>
            <ArticleId IdType="pubmed">25208732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vinogradov S, Reiss A, Csernansky J. Clonidine therapy in withdrawal from high-dose alprazolam treatment. Am J Psychiatry. 1986;143:1188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2875667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White FJ, Kalivas PW. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend. 1998;51:141–153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9716936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willuhn I, Wanat MJ, Clark JJ, et al.  Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse. Behav Neurosci Drug Addict. 2010;3:29–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3766749</ArticleId>
            <ArticleId IdType="pubmed">21161749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolf B, Iguchi MY, Griffiths RR. Sedative/tranquilizer use and abuse in alcoholics currently in outpatient treatment: incidence, pattern and preference. NIDA Res Monograph. 1989;95:376–377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2577042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yonkers KA, Wisner KL, Stowe Z, et al.  Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry. 2004;161:608–620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15056503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zalsman G, Hermesh H, Munitz H. Alprazolam withdrawal delirium: a case report. Clin Neuropharmacol. 1997;21:201–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9617514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zipursky RB, Baker RW, Zimmer B. Alprazolam withdrawal delirium unresponsive to diazepam: case report. J Clin Psychiatry. 1985;46:344–345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2862137</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
